(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Werewolf Therapeutics's earnings in 2026 is -$72,841,000.On average, 8 Wall Street analysts forecast HOWL's earnings for 2026 to be -$72,820,008, with the lowest HOWL earnings forecast at -$88,668,383, and the highest HOWL earnings forecast at -$45,360,817. On average, 6 Wall Street analysts forecast HOWL's earnings for 2027 to be -$87,916,010, with the lowest HOWL earnings forecast at -$104,652,671, and the highest HOWL earnings forecast at -$50,457,538.
In 2028, HOWL is forecast to generate -$81,445,602 in earnings, with the lowest earnings forecast at -$101,322,813 and the highest earnings forecast at -$59,121,964.